Skip to main content

Table 4 Time-Action Profiles of Insulins [44]

From: A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes

Insulin Type Onset Peak (h) Duration of Action (h)
Rapid acting    
Lispro, aspart, glulisine 5–15 min 0.5–1.5 2–4
Inhaled insulin [32] 5–15 min 0.5–1.5 3–6
Short acting    
Regular human 30–60 min 2–3 3–6
Intermediate acting    
Human NPH 2–4 h 4–10 10–16
Long acting (basal)    
Insulin glargine 1–2 h No pronounced peak ≈ 24
Insulin detemir [45] 1–2 h Less pronounced peak (≈ 6) 18–24
  1. Premixed:
  2. Comprised of intermediate-acting insulin with either regular human insulin or a rapid-acting analog in a fixed ratio (eg, 70/30); thus, the onset, peak, and duration reflect the combined effect of these components.
  3. Copyright © 2002 From Insulin therapy in type 2 diabetes mellitus by Ahmann AJ, Riddle MC. In: Leahy JL, Cefalu WT (eds) Insulin Therapy. Reproduced by permission of Routledge/Taylor & Francis Group, LLC